-
Mashup Score: 2Rahul Banerjee: My takeaways from RedirecTT-1 for Fred Hutchinson Cancer Center journal watch - OncoDaily - 19 hour(s) ago
Rahul Banerjee: My takeaways from RedirecTT-1 for Fred Hutchinson Cancer Center journal watch / cancer, Fred Hutchinson Cancer Center, OncoDaily, Oncology,
Source: oncodaily.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 3Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study - 3 day(s) ago
Key Points. D-R maintenance improved MRD-negative conversion rate in NDMM patients who were MRD positive post-transplant, versus R maintenance.PFS favored
Source: ashpublications.orgCategories: General Medicine News, Partners & KOLsTweet-
RT @bdermanmd: And it is published! https://t.co/QBRxpvemIu
-
-
Mashup Score: 2
Myeloma Paper of the Day, January 15th, suggested by Robert Orlowski / ASCT, cancer, Jana Schlenzka, Marc S. Raab, Marc-Andrea Baertsch, Maximilian Merz, MD
Source: oncodaily.comCategories: General Medicine News, Partners & KOLsTweet-
RT @oncodaily: Myeloma Paper of the Day, January 15th, suggested by @Myeloma_Doc https://t.co/FxHYl8nqPl #Cancer #Mmsm #MedEd #MedX #MedN…
-
-
Mashup Score: 10Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma - 3 day(s) ago
In a real-world cohort of relapsed/refractory multiple myeloma patients, bridging with bispecific T cell–engaging antibodies (BsAb) compares favorably to chemotherapy, anti-CD38, and anti-SLAMF7 antibody-based regimens for subsequent BCMA CAR-T cell therapy.
Source: aacrjournals.orgCategories: General Medicine News, Partners & KOLsTweet-
RT @BCD_AACR: Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma https://t.co/lEjPPKwFq2…
-
-
Mashup Score: 25Starting the year smarter - 8 day(s) ago
To start the year right, Fred Hutch scientists, providers and a patient advocate share tips to help readers keep up with the deluge of health and science information.
Source: www.fredhutch.orgCategories: General Medicine News, Partners & KOLsTweet-
Thanks @fredhutch for humoring me about how I try to stay up with the science of #MMsm as an oncologist. This app has changed a lot since I joined… but as long as my colleagues in the myeloma field remain on Twitter, so too will I! 🫡 https://t.co/bFSMWkryrg https://t.co/ryKnzGyBiW
-
-
Mashup Score: 3Joshua Richter: Newly updated NCCN guidelines - OncoDaily - 14 day(s) ago
Joshua Richter: Newly updated NCCN guidelines / cancer, Joshua Richter, NCCN, NCCN guidelines, OncoDaily, Oncology, teclistamab
Source: oncodaily.comCategories: General Medicine News, Partners & KOLsTweet-
RT @oncodaily: ❗️Newly updated NCCN guidelines - @JoshuaRichterMD https://t.co/3NrBK0Q6eR #Cancer #MedEd #MedX #MedNews #Health #Medicine…
-
-
Mashup Score: 1Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure - 15 day(s) ago
Gauthier and colleagues evaluated concomitant ibrutinib and anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in a study of patients with chronic ly
Source: ashpublications.orgCategories: General Medicine News, Partners & KOLsTweet-
RT @drjgauthier: @RahulBanerjeeMD @bitafakhri @btfoundation Shameless self-promotion: https://t.co/Qa6ibUgcmj
-
-
Mashup Score: 92Down with dex! - 16 day(s) ago
In this issue of Blood, Banerjee et al1 present a secondary analysis of pooled data from 2 completed SWOG cooperative group trials (SO777 and S1211), showi
Source: ashpublications.orgCategories: General Medicine News, Partners & KOLsTweet-
And thanks @jmikhaelmd #susieharding for kind commentary about our SWOG dexamethasone analysis, now published in @BloodJournal: #downwithdex now has its first official citation in myeloma #MMsm 👏 Excited to see so much prospective research here now! https://t.co/bGf8dKOTBj https://t.co/C0gVEVhojb https://t.co/yCHCq77bc4
-
-
Mashup Score: 10Toci or not toci: innovations in the diagnosis, prevention, and early management of cytokine release syndrome - 16 day(s) ago
Cytokine release syndrome (CRS) remains a significant toxicity of chimeric antigen receptor T-cell (CAR-T) therapy for hematologic malignancies. While established guidelines exist for the managemen…
Source: www.tandfonline.comCategories: General Medicine News, Partners & KOLsTweet-
4/ And for anyone wondering whether that Shakespeare "Toci or not toci" quote came from, here's our 2021 review of early interventions with toci. Thanks @bitafakhri @ninashah33 for mentorship with writing it! https://t.co/V8CAV2OatO https://t.co/RM3xlLqSyv
-
-
Mashup Score: 5Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience - 16 day(s) ago
Blood Cancer Journal – Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience
Source: www.nature.comCategories: General Medicine News, Partners & KOLsTweet-
3/ Kudos to Emory team @SagarLonialMD @nishjo76 @AjayNookaMD @katmapes @EagleMyeloma @JKaufmanMD for being one of the first to implement this and publish about PPx toci with teclistamab #MMsm in @BloodCancerJnl . Original article here: https://t.co/PE76j1VSey
-
RT @oncodaily: My takeaways from RedirecTT-1 for @fredhutch journal watch - @RahulBanerjeeMD (@UWMedicine) https://t.co/Y7D4GZQRJI #Healt…